Back to search
IDH-mutant Grade 2 or 3 Astrocytoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IDH-mutant Grade 2 or 3 Astrocytoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which IDH-mutant Grade 2 or 3 Astrocytoma trials you may qualify forThe primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared…
This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain fun…
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or ast…